Sign up Australia
Proactive Investors - Run By Investors For Investors

AstraZeneca offloads remaining rights to anaesthetic portfolio to Aspen for US$766mln

“Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas”
medical syringe
AGI will pay US$555mln upfront, followed by a further US$211mln

Drugs giant AstraZeneca PLC (LON:AZN) has agreed to offload the remaining rights to its anaesthetic medicines to a division of Aspen Group for up to US$766mln.

Aspen Global Incorporated (AGI) will acquire the residual rights to Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.

The two parties had already entered into an agreement last summer, under which AGI gained exclusive commercialisation rights to the medicines in markets outside the US.

AGI is now paying an initial US$555mln for the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetics, plus up to a further US$211mln based on performance milestones.

AstraZeneca said it would continue to manufacture and supply the medicines to AGI during a transition period of up to five years.

AstraZeneca, AGI and patients have all benefitted from the successful commercial agreement we established last year,” said Astra’s executive vice president Mark Mallon.

“As our relationship has evolved, AGI has shown that it is in a strong position to maximise the value and reach of the anaesthetic medicines through its extensive commercial network.

“Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas.”

READ: AstraZeneca offloads remaining rights to anaesthetic portfolio to Aspen for US$766mln

Liberum downgrades to ‘hold’ on valuation ground

City broker Liberum has downgraded Astra to ‘hold’ from ‘buy’ as it thinks shares are up with events for the time being.

“As we had expected before Mystic, strong data from FLAURA and PACIFIC have driven Astra's shares almost back to where they were before the PFS failure,” wrote analyst Roger Franklin.

“With this value having come through, the shares are now at c.£49 which in our view fairly prices the ex-Mystic/new 'I-O' business.”

Franklin added that shares could head higher on positive data read-outs, particularly from MYSTIC early next year, but added that the chance of that happening is now “materially lower” after the recent progression-free survival failure.

He upped his price target to £50, slightly higher than £48.56 which is where the share price finds itself this morning.

READ: AstraZeneca lung cancer trial results impress but risks remain, analysts say

--Updates for share price and broker comment--





Register here to be notified of future AZN Company articles
View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
PreveCeutical Medical bidding to be big player in preventive healthcare
October 11 2017
Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years
1506367758_shutterstock_118491940.jpg
September 27 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use